Evaluation of the Clinical Safety and Efficacy of the 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Subjects According to the Indication for Use

Trial Profile

Evaluation of the Clinical Safety and Efficacy of the 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Subjects According to the Indication for Use

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2018

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Arteriosclerosis; Cardiovascular disorders; Coronary artery disease; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2018 Planned primary completion date changed from 30 May 2018 to 31 Jul 2018.
    • 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top